Evaluating Excessive NSAID Use in Ibuprofen Users
The study involved 1326 adults who reported taking ibuprofen-containing medication in the preceding month.
Fifteen percent of adults who took ibuprofen during a 1-week diary study exceeded the maximum recommended daily dose limit (EDL), according to a new study published in Pharmacoepidemiology and Drug Safety.
The study involved 1326 adults who reported taking ibuprofen-containing medication in the preceding month. Using a daily diary, the subjects were asked to note all NSAID use, both over-the-counter (OTC) and prescription, for 1 week.
Results showed that among the participants, 87% took only OTC ibuprofen; 9.5% took prescription ibuprofen products exclusively, and 3.8% took both types. Eleven percent of the ibuprofen-only users had exceeded the daily limit on at least 1 diary day.
Thirty-seven percent of the group also took a second NSAID during the week, mostly aspirin (24%) and naproxen (17%). Overall, when all NSAIDs were considered, 15% of participants exceeded the maximum daily dose on at least 1 diary day.
The percentage of naproxen users who exceeded the recommended daily limit was 23%, significantly higher than for ibuprofen. Twelve ibuprofen users (8.1%) and 20 overall (10%) exceeded the maximum on all 7 days. However, few participants exceeded the daily limit for other NSAIDs.
Factors associated with EDL included male sex (OR, 1.54), ongoing pain (3.19), daily smoking (1.68), and having “choose my dose” (1.47) and “comply with Rx instructions” (1.32) attitudes.
The authors note that the relatively high prevalence of EDL among OTC ibuprofen users is concerning as the drug can be taken without medical supervision. They concluding by stating that "educating consumers about NSAIDs and their dosing directions could reduce excess dosing."
Kaufman DW, Kelly JP, Battista DR, Malone MK, Weinstein RB, Shiffman S. Exceeding the daily dosing limit of nonsteroidal anti-inflammatory drugs among ibuprofen users [published online January 26, 2018]. Pharmacoepidemiol Drug Saf. doi: 10.1002/pds.4391